IM-250 / Innovative Molecules - LARVOL DELTA

Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of IM-250 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=18 | Completed | Sponsor: Innovative Molecules GmbH | Recruiting ➔ Completed | Trial completion date: Aug 2024 ➔ May 2024 | Trial primary completion date: May 2024 ➔ Jan 2024

Trial completion • Trial completion date • Trial primary completion date • Herpes Simplex

Helicase-primase inhibitors for the treatment of herpes simplex virus infections - patent evaluation of WO2023/225162 from gilead sciences inc. (PubMed, Expert Opin Ther Pat) - "With amenamevir already approved for varicella-zoster virus and herpes simplex in Japan and with pritelivir's granted breakthrough therapy designation for the treatment of acyclovir-resistant HSV infections in immunocompromised patients, the target has sparked interest in helicase-primase inhibitors (HPIs)...The asset was contributed to Assembly Biosciences, where it is under development as ABI-1179 at the investigational new drug (IND) enabling stage for high-recurrence genital herpes. A structure proposal for indolinoyl derivative ABI-1179 is presented, showing its potential opportunities and limitations compared to other HPIs."

Journal • Review • Herpes Simplex • Herpes Zoster • Infectious Disease • Varicella Zoster

Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of IM-250 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Innovative Molecules GmbH | Terminated ➔ Recruiting | N=18 ➔ 24 | Trial completion date: May 2024 ➔ Aug 2024

Enrollment change • Enrollment open • Trial completion date • Herpes Simplex

Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Doses of IM-250 in Healthy Volunteers (clinicaltrials.gov) - P1 | N=18 | Terminated | Sponsor: Innovative Molecules GmbH | Trial completion date: Aug 2024 ➔ May 2024 | Recruiting ➔ Terminated | Trial primary completion date: Jan 2024 ➔ May 2024; Three subsequent cohorts completed. Dose saturation almost achieved.

Trial completion date • Trial primary completion date • Trial termination • Herpes Simplex